Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 82 articles: HTML format

Single Articles

April 2026
1. ROUSSEAU A, Foulon S, Planchard D, Remon J, et al
   Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.
   JAMA Oncol. 2026 Apr 9. doi: 10.1001/jamaoncol.2026.0669.
   PubMed     Abstract available
   
   
   March 2026
2. ZHOU H, Wang SC, Lee TTL, Ye ZH, et al
   Combination of Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer.
   JAMA Oncol. 2026 Mar 26. doi: 10.1001/jamaoncol.2026.0392.
   PubMed     Abstract available
   
   
   
3. SINGHI EK, Gandhi SJ, Antonoff MB
   Local Consolidative Therapy in Lung Cancer.
   JAMA Oncol. 2026 Mar 26. doi: 10.1001/jamaoncol.2026.0143.
   PubMed    
   
   
   
4. CHORADIA N, Desai A, Naqash AR
   Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer-When Policy Delays Care.
   JAMA Oncol. 2026 Mar 12. doi: 10.1001/jamaoncol.2025.6459.
   PubMed    
   
   
   
5. LI R, Wang P, Zhang H, Zeng Q, et al
   Lymph Node Dissection Guideline Adherence and Survival in Patients With T1N0M0 Lung Adenocarcinoma.
   JAMA Oncol. 2026;12:266-274.
   PubMed     Abstract available
   
   
   February 2026
6. RAKAEE M, Nassar AH, Tafavvoghi M, Jabar F, et al
   Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
   JAMA Oncol. 2026 Feb 12:e256430. doi: 10.1001/jamaoncol.2025.6430.
   PubMed     Abstract available
   
   
   December 2025
7. KUKHAREVA PV, Li H, Balbin C, Stevens ER, et al
   Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial.
   JAMA Oncol. 2025 Dec 26:e255672. doi: 10.1001/jamaoncol.2025.5672.
   PubMed     Abstract available
   
   
   November 2025
8. AHN BC, Kim YJ, Lee Y, Suh KJ, et al
   Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
   JAMA Oncol. 2025 Nov 26:e255097. doi: 10.1001/jamaoncol.2025.5097.
   PubMed     Abstract available
   
   
   
9. YANG JT, Yerramilli D, Pentsova E, Wolden S, et al
   Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.
   JAMA Oncol. 2025;11:1293-1301.
   PubMed     Abstract available
   
   
   October 2025
10. LIN JK, Xu Y, Xiang JJ, Singhi EK, et al
    Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer.
    JAMA Oncol. 2025 Oct 2:e253768. doi: 10.1001/jamaoncol.2025.3768.
    PubMed    
    
    
    September 2025
11. ANTONOFF MB, Phillips L, Singhi EK
    Understanding Lung Cancer in Younger People.
    JAMA Oncol. 2025 Sep 25. doi: 10.1001/jamaoncol.2025.3320.
    PubMed    
    
    
    
12. DI Y, Song Z, Meng L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3491.
    PubMed    
    
    
    
13. BERTOLACCINI L, de Marinis F, Spaggiari L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3494.
    PubMed    
    
    
    
14. GARBO E, Ricciuti B, Cappuzzo F
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3497.
    PubMed    
    
    
    
15. JONGBLOED M, Bortolot M, Willmann J, Bartolomeo V, et al
    Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2025 Sep 4. doi: 10.1001/jamaoncol.2025.2891.
    PubMed     Abstract available
    
    
    August 2025
16. ROLLE LD, Crane TE
    Methodological Concerns With Lung Cancer Screening Estimates-Reply.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2581.
    PubMed    
    
    
    
17. BURUS T, McAfee CR, Hull PC
    Methodological Concerns With Lung Cancer Screening Estimates.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2584.
    PubMed    
    
    
    June 2025
18. MARKS JA, Liu SV
    Navigating Selective Dose Intensification in EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1768.
    PubMed    
    
    
    
19. LI H, Chen K, Gong L, Qin J, et al
    High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1779.
    PubMed     Abstract available
    
    
    May 2025
20. ROLLE LD
    Coding Errors in Study of Lung Cancer Screening Guidelines and Adherence.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1624.
    PubMed    
    
    
    
21. MARINELLO A, Ghigna MR, Rotow JK, Adeyelu T, et al
    Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1293.
    PubMed     Abstract available
    
    
    
22. RICCIUTI B, Fusco F, Cooper A, Garbo E, et al
    Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115.
    PubMed     Abstract available
    
    
    
23. HEYWARD J, Lesko CR, Murray JC, Mehta HB, et al
    Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.
    PubMed     Abstract available
    
    
    April 2025
24. PIKE LRG, Yu H, Rusthoven CG
    Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.
    JAMA Oncol. 2025 Apr 3. doi: 10.1001/jamaoncol.2025.0188.
    PubMed    
    
    
    March 2025
25. ROLLE LD, Olazagasti C, Lopes G, Rodriguez E, et al
    USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence.
    JAMA Oncol. 2025 Mar 20. doi: 10.1001/jamaoncol.2025.0230.
    PubMed    
    
    
    February 2025
26. SAAL J, Eckstein M, Ritter M, Brossart P, et al
    Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
    JAMA Oncol. 2025;11:154-161.
    PubMed     Abstract available
    
    
    
27. GODDARD KAB, Feuer EJ, Mandelblatt JS, Meza R, et al
    Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.
    JAMA Oncol. 2025;11:162-167.
    PubMed     Abstract available
    
    
    December 2024
28. RAKAEE M, Tafavvoghi M, Ricciuti B, Alessi JV, et al
    Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5356.
    PubMed     Abstract available
    
    
    November 2024
29. MALHOTRA J, Mambetsariev I, Gilmore G, Fricke J, et al
    Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review.
    JAMA Oncol. 2024 Nov 27. doi: 10.1001/jamaoncol.2024.5218.
    PubMed     Abstract available
    
    
    
30. CHENG Y, Zhang W, Wu L, Zhou C, et al
    Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
    JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.5019.
    PubMed     Abstract available
    
    
    
31. CALI DAYLAN AE, Morgensztern D, Waqar SN
    Toripalimab For Extensive-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.4958.
    PubMed    
    
    
    October 2024
32. ASAHINA H, Tsukita Y, Tozuka T
    Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4757.
    PubMed    
    
    
    
33. TU H, Zhang Y, You Z
    Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4754.
    PubMed    
    
    
    September 2024
34. ZHANG L, Li J, Guo L
    Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4211.
    PubMed    
    
    
    
35. SORIN M, Prosty C, Spicer JD
    Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4214.
    PubMed    
    
    
    
36. HU C
    Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Sep 19. doi: 10.1001/jamaoncol.2024.2905.
    PubMed    
    
    
    
37. SWAMINATH A, Parpia S, Wierzbicki M, Kundapur V, et al
    Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2024 Sep 19:e243089. doi: 10.1001/jamaoncol.2024.3089.
    PubMed     Abstract available
    
    
    August 2024
38. HONG MH, Choi YJ, Ahn HK, Lim SM, et al
    Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2640.
    PubMed     Abstract available
    
    
    
39. CHENG H
    The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2607.
    PubMed    
    
    
    
40. HATTON JN, Kucera J, Seastedt KP, de Andrade KC, et al
    Characterizing Lung Cancer in Li-Fraumeni Syndrome.
    JAMA Oncol. 2024 Aug 1:e242511. doi: 10.1001/jamaoncol.2024.2511.
    PubMed    
    
    
    
41. LEE JM
    Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung Carcinoma.
    JAMA Oncol. 2024 Aug 1. doi: 10.1001/jamaoncol.2024.2294.
    PubMed    
    
    
    
42. ALTORKI N, Wang X, Damman B, Jones DR, et al
    Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Seconday Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Aug 1:e242491. doi: 10.1001/jamaoncol.2024.2491.
    PubMed     Abstract available
    
    
    July 2024
43. ROSS HJ, Kozono D, Wang XF, Urbanic JJ, et al
    Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jul 25. doi: 10.1001/jamaoncol.2024.1897.
    PubMed     Abstract available
    
    
    
44. TSAI CH, Chiang PH
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2453.
    PubMed    
    
    
    
45. TAKEMURA N, Lin CC
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer-Reply.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2456.
    PubMed    
    
    
    June 2024
46. CHUN SG, Hu C, Komaki RU, Timmerman RD, et al
    Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Jun 27. doi: 10.1001/jamaoncol.2024.1841.
    PubMed     Abstract available
    
    
    
47. DONG S, Wang Z, Zhang JT, Yan B, et al
    Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Jun 13. doi: 10.1001/jamaoncol.2024.1779.
    PubMed     Abstract available
    
    
    May 2024
48. CHAUNZWA TL, Qian JM, Li Q, Ricciuti B, et al
    Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2024 May 23. doi: 10.1001/jamaoncol.2024.1120.
    PubMed     Abstract available
    
    
    
49. SORIN M, Prosty C, Ghaleb L, Nie K, et al
    Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
    JAMA Oncol. 2024;10:621-633.
    PubMed     Abstract available
    
    
    
50. ROLFO C, Russo A
    The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are A-Changin'.
    JAMA Oncol. 2024;10:569-570.
    PubMed    
    
    
    April 2024
51. NORONHA V, Patil V, Menon N, Shah M, et al
    Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Apr 25. doi: 10.1001/jamaoncol.2024.0584.
    PubMed    
    
    
    
52. RODRIGUES G, Higgins KA, Rimner A, Amini A, et al
    American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 11. doi: 10.1001/jamaoncol.2024.0294.
    PubMed     Abstract available
    
    
    
53. AKAMATSU H
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0231.
    PubMed    
    
    
    
54. TACHIHARA M, Tsujino K
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0234.
    PubMed    
    
    
    
55. SZLOSAREK PW, Creelan BC, Sarkodie T, Nolan L, et al
    Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
    JAMA Oncol. 2024;10:475-483.
    PubMed     Abstract available
    
    
    March 2024
56. ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al
    Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023.
    PubMed     Abstract available
    
    
    
57. TSUKITA Y, Tozuka T, Kushiro K, Hosokawa S, et al
    Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.6277.
    PubMed     Abstract available
    
    
    
58. PALMA DA, Bahig H, Hope A, Harrow S, et al
    Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.7269.
    PubMed     Abstract available
    
    
    
59. KEREKES DM, Frey AE, Prsic EH, Tran TT, et al
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
    JAMA Oncol. 2024;10:342-351.
    PubMed     Abstract available
    
    
    January 2024
60. ARRIETA O, Cardenas-Fernandez D, Rodriguez-Mayoral O, Gutierrez-Torres S, et al
    Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5232.
    PubMed     Abstract available
    
    
    
61. LESTER-COLL NH, Park HS
    Stereotactic Body Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer-Is This the Future?
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5856.
    PubMed    
    
    
    
62. WU TC, Luterstein E, Neilsen BK, Goldman JW, et al
    Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.6033.
    PubMed     Abstract available
    
    
    
63. NOGUEIRA LM, Liu Y
    Wildfire Exposure and Lung Cancer Survival-Reply.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6126.
    PubMed    
    
    
    
64. OZAKI A, Murakami M, Leppold C
    Wildfire Exposure and Lung Cancer Survival.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6123.
    PubMed    
    
    
    
65. OKUMA Y, Kubota K, Shimokawa M, Hashimoto K, et al
    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2024;10:43-51.
    PubMed     Abstract available
    
    
    December 2023
66. WEST HJ, Kim JY
    Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    JAMA Oncol. 2023 Dec 28. doi: 10.1001/jamaoncol.2023.5276.
    PubMed     Abstract available
    
    
    
67. SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al
    Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 21. doi: 10.1001/jamaoncol.2023.5258.
    PubMed     Abstract available
    
    
    
68. TEWARI KS, Colombo N, Monk BJ, Dubot C, et al
    Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 14. doi: 10.1001/jamaoncol.2023.5410.
    PubMed     Abstract available
    
    
    
69. TAKEMURA N, Cheung DST, Fong DYT, Lee AWM, et al
    Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 7. doi: 10.1001/jamaoncol.2023.5248.
    PubMed     Abstract available
    
    
    November 2023
70. BONNER SN, Curley R, Love K, Akande T, et al
    Structural Racism and Lung Cancer Risk: A Scoping Review.
    JAMA Oncol. 2023 Nov 30. doi: 10.1001/jamaoncol.2023.4897.
    PubMed     Abstract available
    
    
    
71. WANG VE, Gainor JF
    Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004.
    PubMed    
    
    
    
72. KIM TW, Bedard PL, LoRusso P, Gordon MS, et al
    Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1574-1582.
    PubMed     Abstract available
    
    
    
73. GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al
    Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1525-1534.
    PubMed     Abstract available
    
    
    October 2023
74. CHOI E, Ding VY, Luo SJ, Ten Haaf K, et al
    Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4447.
    PubMed     Abstract available
    
    
    
75. SEQUIST LV, Warner ET, Yang CJ
    Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4410.
    PubMed    
    
    
    
76. JEMAL A, Schafer EJ, Sung H, Bandi P, et al
    The Burden of Lung Cancer in Women Compared With Men in the US.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4415.
    PubMed    
    
    
    
77. TAKAHASHI N, Hao Z, Villaruz LC, Zhang J, et al
    Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4025.
    PubMed     Abstract available
    
    
    
78. LEI J, Zhao J, Gong L, Ni Y, et al
    Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1348-1355.
    PubMed     Abstract available
    
    
    September 2023
79. ALDEA M, Marinello A, Guyon D, Gazzah A, et al
    Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.
    JAMA Oncol. 2023 Sep 14. doi: 10.1001/jamaoncol.2023.3625.
    PubMed    
    
    
    
80. TACHIHARA M, Tsujino K, Ishihara T, Hayashi H, et al
    Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3309.
    PubMed     Abstract available
    
    
    
81. GRECO L
    Patients With Brain Metastases Deserve Better-A Hard-Won Perspective.
    JAMA Oncol. 2023;9:1197-1198.
    PubMed    
    
    
    
82. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum